Subscribe to RSS
Download PDF
DOI: 10.1055/s-0037-1622548
Diagnostik und Therapieverlauf eines kaninen malignen multizentrischen Lymphoms mit Augenbeteiligung
Ein FallberichtCanine malignant multicentric lymphoma with ocular involvement: Diagnosis and response to chemotherapyPublication History
Eingegangen:
15 June 2005
akzeptiert:
17 November 2005
Publication Date:
05 January 2018 (online)
Zusammenfassung
Gegenstand und Ziel: Darstellung der Diagnostik, Therapie und des klinischen Verlaufs eines malignen Lymphoms mit Augenbeteiligung bei einem Hund. Untersuchungsgut, Material und Methode: Fallbericht eines achtjährigen männlichen Labradors. Darstellung der Diagnostik und des Stagings des malignen Lymphoms sowie der Behandlung mit Kombinationschemotherapie. Ergebnisse: Eine komplette Remission wurde erzielt. Die Gesamtüberlebenszeit des Hundes bei guter Lebensqualität beträgt derzeit 1888 Tage (4,5 Jahre). Schlussfolgerung: Auch bei Vorliegen eines kaninen malignen Lymphoms mit Augenbeteiligung kann mithilfe einer geeigneten Chemotherapie ein gutes Therapieergebnis hinsichtlich der Überlebenszeit und bei Fällen ohne Ablatio retinae auch hinsichtlich des Visus des Patienten erzielt werden. Klinische Relevanz: Die Prognose des malignen Lymphoms des Hundes mit okularer Beteiligung ist nicht in jedem Fall als infaust anzusehen, sodass eine Chemotherapie bei diesen Patienten durchaus in Betracht kommt.
Summary
Objective: Presentation of the diagnosis, response and clinical course following combination chemotherapy in a dog with malignant multicentric lymphoma displaying ocular involvement. Study design: Clinical case report. Sample population: One eight-year-old male Labrador retriever. Results: Complete remission was achieved with cyclic combination chemotherapy. Overall survival time with good quality of life of the dog that is still alive to date amounts to 1,888 days (4.5 years). Conclusion: By use of combination chemotherapy a good treatment result can also be achieved in dogs with malignant lymphoma that display ocular manifestation. Clinical relevance: The presented case shows that the prognosis of canine malignant lymphoma with ocular involvement must not be judged as guarded in every case and that chemotherapeutic treatment can represent a feasible and beneficial treatment option.
-
Literatur
- 1 Allgöwer I, Stockhaus C, Schäffer EH. Malignes Lymphom mit okulärer Manifestation bei einem Hund. Tierärztl Prax 2003; 31 (K): 99, 124-5.
- 2 Bäckgren AW. Lymphatic leukosis in dogs. An epizootiological clinical and haematological study. Acta Vet Scand. 1965 06. Suppl I.
- 3 Bell R, Cotter SM, Lillquist A. Characterization of glucocorticoid receptors in animal lymphoblastic disease: correlation with response to single agent glucocorticoid treatment. Blood 1984; 63: 380-3.
- 4 Carter RF, Harris CK, Withrow SJ. Chemotherapy of canine lymphoma with histopathological correlation: doxorubicin alone compared to COP as first treatment regimen. J Am Anim Hosp Assoc 1987; 23: 587-96.
- 5 Cello RM, Hutcherson B. Ocular changes in malignant lymphoma of dogs. Cornell Vet 1962; 52: 493-523.
- 6 Couto CG. Canine lymphomas: something old, something new. Comp Cont Educ Pract Vet 1985; 07: 291-302.
- 7 Couto CG, Rutgers HC, Sherding RG, Rojko J. Gastrointestinal lymphoma in 20 dogs: A retrospective study. J Vet Intern Med 1989; 03: 73-8.
- 8 Couto CG, Cullen J, Pedroia V, Turrel JM. Central nervous system lymphosarcoma in the dog. J Am Vet Med Assoc 1984; 184: 809-13.
- 9 Culmsee K, Simon D, Mischke R, Nolte I. Possibilities of flow cytometric analysis for immunophenotypic characterization of canine lymphoma. J Vet Med A Physiol Pathol Clin Med 2001; 48 (04) 199-206.
- 10 Dorn CR, Taylor DON, Hibbard HH. Epizootiologic characteristics of canine and feline leukemia and lymphoma. Am J Vet Res 1967; 28: 993-1001.
- 11 Greenlee PG, Filippa DA, Quimby FW, Patnaik AK, Calvano SE, Matus RE, Kimmel M, Hurvitz AI, Lieberman PH. Lymphomas in dogs. A morphologic, immunologic, and clinical study. Cancer 1990; 66: 480-90.
- 12 Gwin RM, Gelatt KN, Williams LW. Ophthalmic neoplasms in the dog. J Am Anim Hosp Assoc 1982; 18: 853-66.
- 13 Hahn KA, Richardson RC, Teclaw RF, Cline JM, Carlton WW, DeNicola DB, Bonney PL. Is maintenance chemotherapy appropriate for the management for canine malignant lymphoma?. J Vet Intern Med 1992; 06: 3-10.
- 14 Hardy WD, Old LJ. L-asparaginase in the treatment of neoplastic diseases of the dog, cat and cow. Recent Results Cancer Res 1970; 33: 131-9.
- 15 Krohne SG, Henderson NM, Richardson RC, Vestre WA. Prevalence of ocular involvement in dogs with multicentric lymphoma: prospective evaluation of 94 cases. Vet Comp Ophthalmol 1994; 04: 127-35.
- 16 MacEwen EG, Hayes AA, Matus RE, Kurzman I. Evaluation of some prognostic factors for advanced multicentric lymphosarcoma in the dog. 147 cases (1978-1981) J Am Vet Med Assoc 1987; 190: 564-8.
- 17 MacEwen EG, Rosenthal RC, Fox LE, Loar AS, Kurzman ID. Evaluation of L-asparaginase: polyethylene glycol conjugate versus nativ L-asparaginase combined with chemotherapy. A randomized double-blind study in canine lymphoma.J Vet Intern Med 1992; 06: 230-4.
- 18 Madewell BR, Theilen GH. Hematopoietic neoplasms, sarcomas and related conditions. Part IV: Canine. In: Veterinary Cancer Medicine. 2nd ed.. Theilen GH, Madewell BR. eds. Philadelphia: Lea & Febiger; 1987: 392-407.
- 19 Martin CL. Augenkrankheiten bei Hund und Katze (Pferd und Wiederkäuer). Alfeld: Schaper; 1995
- 20 Massa KL, Gilger BC, Miller TL, Davidson MG. Causes of uveitis in dogs: 102 cases (1989-2000). Vet Ophthal 2002; 05: 93-8.
- 21 Meyer-Lindenberg A, Wagner F. Tumoren des Auges und der Adnexe. In: Praxis der Onkologie bei Hund und Katze. Nolte I, Nolte M. Hrsg. Stuttgart: Enke; 2000: 155-99.
- 22 Miller PE, Dubielzig R. Ocular tumors. In: Small Animal Clinical Oncology. 2nd ed.. Withrow SJ, MacEwen EG. eds. Philadelphia: Saunders; 1995: 420-31.
- 23 Peiffer RL, Simons KB. Canine ocular lymphosarcoma. In: Ocular Tumors in Animals und Humans. Peiffer RL, Simons KB. eds. Philadelphia: Iowa State Press; 2002: 381-3.
- 24 Pelt van RW, Connor GH. Clinicopathologic survey of malignant lymphoma in the dog. J Am Vet Med Assoc 1968; 152: 976-89.
- 25 Postorino NC, Susaneck SJ, Withrow SJ. Single agent therapy with Adriamycin for canine lymphosarcoma. J Am Anim Hosp Assoc 1989; 25: 221-5.
- 26 Rosin A. Neurologic disease associated with lymphosarcoma in ten dogs. J Am Vet Med Assoc 1982; 181: 50-3.
- 27 Squire RA, Bush M, Melby EC, Neeley LM, Yarbrough B. Clinical and pathologic study of canine lymphoma: clinical staging, cell classification, and therapy. J Nat Cancer Inst 1973; 51: 565-74.
- 28 Swanson JF. Ocular manifestation of systemic disease. Vet Clin North Am Small Anim Pract 1990; 20: 849-67.
- 29 Teske E. Canine malignant lymphoma: a review and comparison with human non-Hodgkin’s lymphoma. Vet Quart 1994; 16: 209-19.
- 30 Teske E, van Heerde P, Rutteman GR, Kurzman ID, Moore PF, MacEwen EG. Prognostic factors in canine non-Hodgkin’s lymphomas. A prospective study in 138 dogs. J Am Vet Med Assoc 1994; 205: 1722-8.
- 31 Teske E, Rutteman GR, van Heerde P, Misdorp W. Polyethylene glycol-L-asparaginase in canine non-Hodgkin’s lymphoma. Eur J Cancer 1990; 26: 891-5.
- 32 Vail DM, Kisseberth WC, Obradovich JE, Moore FM, London CA, Mac-Ewen EG, Ritter MA. Assessment of potential doubling time (Tpot), argyrophilic nucleolar organizer regions (AgNOR), and proliferating cell nuclear antigen (PCNA) as predictors of therapy response in canine malignant lymphoma. Exp Hematol 1996; 24: 807-15.
- 33 Vail DM, MacEwen EG, Young KM. Canine lymphomas and lymphoid leukemias. In: Small Animal Clinical Oncology. 3rd ed.. Withrow SJ, MacEwen EG. eds. Philadelphia: Saunders; 2001: 558-90.